ASX:BNO

Bionomics (BNO) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
386,458 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Bionomics

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.

BNO Stock News Headlines

Bionomics ADR (BNOX) Earnings Dates & Reports
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Bionomics Ltd: Bionomics' Half-Year Report
Will Bionomics (ASX:BNO) Spend Its Cash Wisely?
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Quarterly Activities Report for September 2022
Bionomics Investor Webinar
Bionomics Limited (BNO.AX)
Bionomics' Half-Year Report
Bionomics Limited (Nasdaq: BNOX, ASX: BNO) to...
See More Headlines
Receive BNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bionomics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2019
Today
4/26/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-24,910,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$6.02 million
Book Value
A$0.03 per share

Miscellaneous

Outstanding Shares
1,470,000,000
Free Float
N/A
Optionable
Not Optionable
Beta
2.13
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Adrian Hinton BEC (Age 70)
    F.C.A., Financial Controller
    Comp: $323.78k
  • Dr. Spyridon Papapetropoulos M.D. (Age 50)
    Ph.D., CEO, Pres & Director
  • Mr. Timothy M. Cunningham CPA (Age 60)
    CPA, M.B.A., Chief Financial Officer
  • Prof. Paul Rolan D.C.P.S.A.
    F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Consultant Chief Medical Officer of Clinical Neuroscience
  • Dr. Julie Kerner Ph.D.
    Sr. VP of Bus. Operations
  • Dr. Atul R. Mahableshwarkar DFAPA
    M.D., Acting Chief Medical Officer
  • Ms. Suzanne Irwin B.Com.
    FCIS, Company Sec.

BNO Stock Analysis - Frequently Asked Questions

How were Bionomics' earnings last quarter?

Bionomics Limited (ASX:BNO) announced its quarterly earnings results on Friday, February, 15th. The company reported ($0.02) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Bionomics own?
This page (ASX:BNO) was last updated on 4/26/2024 by MarketBeat.com Staff

From Our Partners